Xencor(XNCR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Xencor Reports Second Quarter 2024 Financial Results PASADENA, Calif.--Aug. 5, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2024 and provided a review of recent business updates and internal clinical-stage programs. "Xencor's clinical focus is developing high-potential, first-in-class bispecific T-cell en ...